CD33 and acute myeloid leukemia: Some targeted therapies have been validated either in an association with the backbone of 3 + 7 or alone such as midostaurine for FLT3 mutated AML patients,2 ivosidenib for IDH1 mutated AML patients, enasidenib for IDH2 AML6 mutated patients, and gemtuzumab ozogamycin for CD33‐positive AML patients.7